Global No.1
NTLis specializing in female cancer
with the world’s most advanced technology in the field of Cervicography,
A medical device for early diagnosis of uterine cervical cancer.
6,000,000
Images
27
Business Experience
80
Market share in Korea
Ref) Internal Market Research
500000
Every year
Here we introduce
the main businesses of NTL
- CerviCARE® AI is a cervical cancer diagnosis-assistance system Based on artificial intelligence
- The introduction of CerviCARE® AI increases the speed and accuracy of diagnosis and medical treatment.
- CerviCARE AI enables to see get the results in a few seconds at the Point-of-Care.
- If an abnormality is found, it can be consulted by requesting reading to 45 professors specializing in gynecologic oncology at 32 university hospitals.
NOTICE
Title | Date | |
---|---|---|
NTL Healthcare official website renewal
|
2023.05.31 | |
Release CerviCARE AI Service
|
2023.05.31 | |
TFDA Approval (Thailand Food and Drug Administration)
|
2023.05.31 | |
Clinical study with University of Sao Paulo in Brazil
|
2023.05.31 |